Stock ADTX ADITXT, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Aditxt, Inc.

Equities

ADTX

US0070256047

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
2.39 USD -5.53% Intraday chart for Aditxt, Inc. +1.70% -63.95%
Apr. 16 Aditxt, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Apr. 02 Appili Therapeutics To be Acquired by Aditxt, Inc. MT

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 25.54 23.32 4.96 8.28
Enterprise Value (EV) 1 16.87 20.17 5.573 26.4
P/E ratio - - -0.08 x -0.06 x
Yield - - - -
Capitalization / Revenue - 222,036,883 x 5,311,791 x 12,834,213 x
EV / Revenue - 192,041,567 x 5,968,543 x 40,920,944 x
EV / EBITDA -1,905,744 x -745,257 x -227,399 x -1,030,195 x
EV / FCF -3.07 x -1.69 x -0.46 x -1.91 x
FCF Yield -32.6% -59% -219% -52.3%
Price to Book - 2.34 x 0.95 x 0.54 x
Nbr of stocks (in thousands) 6.14 21.8 107 1,249
Reference price 2 4,160 1,072 46.18 6.630
Announcement Date 3/25/21 3/31/22 4/17/23 4/16/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - - - 0.105 0.9337 0.6452
EBITDA - - -8.854 -27.07 -24.51 -25.63
EBIT 1 -5.609 -5.871 -8.872 -27.43 -24.94 -26.06
Operating Margin - - - -26,120.04% -2,670.64% -4,039.58%
Earnings before Tax (EBT) 1 -5.689 -5.828 -9.149 -46.37 -27.65 -32.39
Net income 1 -5.689 -5.828 -9.149 -46.37 -27.65 -32.38
Net margin - - - -44,148.91% -2,961.28% -5,018.92%
EPS - - - - -595.5 -108.2
Free Cash Flow 1 1.747 1.883 -5.497 -11.91 -12.23 -13.81
FCF margin - - - -11,339.92% -1,309.33% -2,139.78%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 1/15/20 2/19/20 3/25/21 3/31/22 4/17/23 4/16/24
1USD in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q3 2022 Q4 2023 Q1 2023 Q3
Net sales 1 0.3231 0.1856 0.2184 0.1245
EBITDA - - - -
EBIT 1 -5.392 -8.2 -5.985 -8.095
Operating Margin -1,668.73% -4,418.13% -2,740% -6,502.7%
Earnings before Tax (EBT) - - - -
Net income -7.558 - - -
Net margin -2,338.86% - - -
EPS -210.8 - - -
Dividend per Share - - - -
Announcement Date 11/14/22 4/17/23 5/15/23 11/14/23
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 0.05 0.16 - - 0.61 18.1
Net Cash position 1 - - 8.66 3.15 - -
Leverage (Debt/EBITDA) - - - - -0.025 x -0.7071 x
Free Cash Flow 1 1.75 1.88 -5.5 -11.9 -12.2 -13.8
ROE (net income / shareholders' equity) 713% 266% -224% -438% -359% -305%
ROA (Net income/ Total Assets) -4,983% -3,067% -83.9% -115% -114% -58.9%
Assets 1 0.1142 0.19 10.91 40.24 24.3 54.98
Book Value Per Share - - - 458.0 48.40 12.20
Cash Flow per Share - - - 354.0 25.70 0.0700
Capex - - 0.17 1.02 0.37 0.01
Capex / Sales - - - 967.07% 39.31% 2.23%
Announcement Date 1/15/20 2/19/20 3/25/21 3/31/22 4/17/23 4/16/24
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ADITXT, INC. Stock Aditxt, Inc.
-63.95% 3.98M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ADTX Stock
  4. Financials Aditxt, Inc.